A Study of Benralizumab to Reduce Oral Corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma (PONENTE Study)

What we are studying

The purpose for the study is to determine how effective and safe the treatment benralizumab is in reducing the use of oral corticosteroid (a medication that helps reduce inflammation) for severe eosinophilic asthma treatment.

Who is Eligible

  • All Genders
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Diagnosed with Severe Eosinophilic Asthma
  • Taking Oral Corticosteroid Treatment
  • Further Criteria Will Be Discussed with Study Team

What is involved

  • Informed Consent Review
  • Review of Medical History
  • Physical Examinations
  • Phone Calls and/or Emails
  • Study Visits and Consultations
  • Surveys/Questionnaires
  • Laboratory and Imaging Tests
  • Specimen Sample Collection
  • Use of Study Treatments or Placebo
  • After Study Follow-Up Activities

Compensation

Compensation will be discussed with the potential participant

Contact Information

Study Coordinator
Wendy Moore
Email
bhmieles@wakehealth.edu
Phone
(336) 713-8550

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.